This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
=== Research funding === In March 2023, SHIELD Illinois hosted a COVID-19 research symposium to spotlight the vital role of research in confronting future public health emergencies. In addition to seminars and speakers, researchers had the opportunity to apply for funding from SHIELD Illinois for projects related to SARS-CoV-2 and COVID-19.
== Risk factors == End organ dysfunction (liver disease), which may lead to decreased drug clearance, is a risk factor for opioid overdose. Other risk factors for opioid overdose include sleep disordered breathing disorders such as sleep apnea, pulmonary diseases (such as asthma or chronic obstructive pulmonary disease) which may reduce ventilation and concomitant use of sedating medications such as benzodiazepines, gabapentinoids, muscle relaxants and other central nervous system depressants. Benzodiazepine use with opioids increases the risk of overdose death by four-fold, whereas concomitant use with gabapentintoids such as gabapentin or pregabalin increases the risk of overdose death by nearly two-fold. Higher doses of prescription opioids, as well as long-acting formulations, are associated with an increased risk of overdose. In those on long-term opioid treatment for chronic pain, daily morphine equivalents greater than 200 mg were associated with death from opioid related causes (including overdose) in 3.8% of men and 2.2% of women. Opioids are the most common cause for serious accidental poisonings of children in the UK.
== Veterinary uses == A number of veterinary medicine teaching hospitals are participating in a long-term clinical study examining the effect of rapamycin on the longevity of dogs. A clinical trial led by NC State College of Veterinary Medicine (HALT), run at a number of veterinary hospitals across the US, found that rapamycin reverses the effects of hypertrophic cardiomyopathy in cats. In March 2025, the US Food and Drug Administration announced conditional approval of sirolimus delayed-release tablets (Felycin-CA1) for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy. This is the first product approved for use in cats with hypertrophic cardiomyopathy for any indication. Cardiomyopathy is a disease of the heart muscle. Hypertrophic cardiomyopathy in cats causes thickening of the heart's left ventricle. It is the most common heart disease in cats and is one of the most common causes of death in cats. While the cause is unknown in most cases, hypertrophic cardiomyopathy is associated with a genetic mutation in certain breeds, such as Maine Coons, Ragdolls, and Persians. Hypertrophic cardiomyopathy is a progressive disease. Cats in the subclinical phase have thickening of their heart wall but do not show clinical symptoms of the disease yet. Cats may live for years in the subclinical phase, while others may progress to congestive heart failure, arterial thromboembolism, or sudden death.
Sources: en.wikipedia.org
==== Chemically reactive agents ==== Agents such as hydrogen peroxide, elemental chlorine, hypochlorous acid (chlorine water), bromine, bromine water, iodine, nitric and oxidising acids, and ozone react with sensitive moieties such as sulfide/thiol, activated aromatic rings (phenylalanine) in effect damage the protein and render it useless.
=== Barbiturates === Barbiturates are powerful anxiolytics but the risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.
After the Qatari Ministry of Defence announced on 2 March that two Iranian drones attacked Qatari gas facilities, followed closely by an announcement from QatarEnergy that all gas production in the country had been halted, European natural gas prices nearly doubled. This raised concerns over energy security and fertiliser costs. EU natural gas prices decreased again to a less-high €48/MWh on Wednesday 4 March. The Iran conflict also bolstered the necessity for renewable energy, as solar and wind power can reduce vulnerability to external supply and decentralised power generation that offers greater autonomy from global energy markets. With fluctuating oil prices, renewable energy has become significantly more cost-competitive. April 2026 was the strongest month of electric vehicle sales on record in Europe. Shell plc's CEO warned that Europe could face shortages of fuel by April. British supermarket chain Asda warned that it was already facing shortages of fuel at their fuel stations. In addition to broader fuel supply disruptions, reports in April 2026 indicated significant impacts on global energy and aviation markets linked to tensions in the Strait of Hormuz during the Iran–United States conflict. Restricted maritime traffic was reported to have contributed to supply constraints in oil and jet fuel, affecting global energy flows and increasing market volatility. The disruption contributed to sharp increases in global energy prices.
== Oxford == Oxford University Press, which publishes the Oxford English Dictionary and many other dictionaries, announces an Oxford Dictionaries UK Word of the Year and an Oxford Dictionaries US Word of the Year; sometimes these are the same word and simply dubbed Word of the Year. The word need not have been coined within the year or twelve months but it does need to have become prominent or notable during that time. There is no guarantee that the Word of the Year will be included in any Oxford dictionary if it's not present. The Oxford Dictionaries Words of the Year are selected by editorial staff from each of the Oxford dictionaries. The selection team is made up of lexicographers and consultants to the dictionary team, and editorial, marketing, and publicity staff.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.